

Michelle Lavin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8616979/publications.pdf>

Version: 2024-02-01

48
papers

1,021
citations

516561

16
h-index

454834

30
g-index

49
all docs

49
docs citations

49
times ranked

1086
citing authors

#	ARTICLE	IF	CITATIONS
1	ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Advances, 2021, 5, 301-325.	2.5	152
2	Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels. Blood, 2017, 130, 2344-2353.	0.6	98
3	Von Willebrand factor propeptide in severe coronavirus disease 2019 (COVID-19): evidence of acute and sustained endothelial cell activation. British Journal of Haematology, 2021, 192, 714-719.	1.2	92
4	Significant gynecological bleeding in women with low von Willebrand factor levels. Blood Advances, 2018, 2, 1784-1791.	2.5	79
5	ADAMTS13 regulation of VWF multimer distribution in severe COVID-19. Journal of Thrombosis and Haemostasis, 2021, 19, 1914-1921.	1.9	58
6	von Willebrand factor clearance – biological mechanisms and clinical significance. British Journal of Haematology, 2018, 183, 185-195.	1.2	51
7	Vaccine-induced immune thrombotic thrombocytopenia (VITT) – a novel clinico-pathological entity with heterogeneous clinical presentations. British Journal of Haematology, 2021, 195, 76-84.	1.2	42
8	Barriers and challenges faced by women with congenital bleeding disorders in Europe: Results of a patient survey conducted by the European Haemophilia Consortium. Haemophilia, 2019, 25, 468-474.	1.0	38
9	How I treat low von Willebrand factor levels. Blood, 2019, 133, 795-804.	0.6	36
10	Increased galactose expression and enhanced clearance in patients with low von Willebrand factor. Blood, 2019, 133, 1585-1596.	0.6	32
11	An international survey to inform priorities for new guidelines on von Willebrand disease. Haemophilia, 2020, 26, 106-116.	1.0	32
12	von Willebrand factor arginine 1205 substitution results in accelerated macrophage-dependent clearance in vivo. Journal of Thrombosis and Haemostasis, 2015, 13, 821-826.	1.9	28
13	Lenalidomide as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy. Journal of Thrombosis and Haemostasis, 2016, 14, 1200-1205.	1.9	27
14	New treatment approaches to von Willebrand disease. Hematology American Society of Hematology Education Program, 2016, 2016, 683-689.	0.9	27
15	Galectin-1 and Galectin-3 Constitute Novel-Binding Partners for Factor VIII. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 855-863.	1.1	23
16	European principles of care for women and girls with inherited bleeding disorders. Haemophilia, 2021, 27, 837-847.	1.0	23
17	Gynecologic and obstetric management of women with von Willebrand disease: summary of 3 systematic reviews of the literature. Blood Advances, 2022, 6, 228-237.	2.5	15
18	Perioperative management of patients with von Willebrand disease. Hematology American Society of Hematology Education Program, 2019, 2019, 604-609.	0.9	14

#	ARTICLE	IF	CITATIONS
19	X-linked moyamoya syndrome associated with severe haemophilia A. <i>Haemophilia</i> , 2016, 22, e51-e54.	1.0	12
20	Clinical management of woman with bleeding disorders: A survey among European haemophilia treatment centres. <i>Haemophilia</i> , 2020, 26, 657-662.	1.0	12
21	Current Challenges in the Peripartum Management of Women with von Willebrand Disease. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 217-228.	1.5	12
22	A systematic review of physical activity in people with haemophilia and its relationship with bleeding phenotype and treatment regimen. <i>Haemophilia</i> , 2021, 27, 544-562.	1.0	12
23	Standardizing care to manage bleeding disorders in adolescents with heavy mensesâ€”A joint project from the ISTH pediatric/neonatal and women's health SSCs. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2759-2774.	1.9	11
24	PT-VWD posing diagnostic and therapeutic challenges â€” small case series. <i>Platelets</i> , 2017, 28, 484-490.	1.1	9
25	Harnessing Twitter to empower scientific engagement and communication: The ISTH 2020 virtual congress experience. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, 253-260.	1.0	8
26	A role for intravenous immunoglobulin in the treatment of Acquired Von Willebrand Syndrome associated with IgM gammopathy. <i>Haemophilia</i> , 2018, 24, e22-e25.	1.0	7
27	Management of elective procedures in low von Willebrand factor patients in the LoVIC study. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 701-710.	1.9	7
28	Examining international practices in the management of pregnant women with von Willebrand disease. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 82-91.	1.9	7
29	Pain and functional disability amongst adults with moderate and severe haemophilia from the Irish personalised approach to the treatment of haemophilia (iPATH) study. <i>European Journal of Haematology</i> , 2022, 108, 518-527.	1.1	7
30	Age-related factor IX correction in symptomatic female carriers with haemophilia B Leyden. <i>Haemophilia</i> , 2015, 21, e498-e500.	1.0	5
31	Missed at first Glanz: Glanzmann thrombasthenia initially misdiagnosed as Von Willebrand Disease. <i>Transfusion and Apheresis Science</i> , 2019, 58, 58-60.	0.5	5
32	Transfusion requirements in patients with COVIDâ€”19. <i>European Journal of Haematology</i> , 2021, 106, 132-134.	1.1	5
33	Validation of Risk-Adapted Venous Thromboembolism Prediction in Multiple Myeloma Patients. <i>Journal of Clinical Medicine</i> , 2021, 10, 3536.	1.0	5
34	von Willebrand disease: proposing definitions for future research. <i>Blood Advances</i> , 2021, 5, 565-569.	2.5	5
35	Longitudinal bleeding assessment in von willebrand disease utilising an interim bleeding score. <i>Journal of Thrombosis and Haemostasis</i> , 0, , .	1.9	5
36	Management of combined factor V and factor VIII deficiency in pregnancy. <i>Journal of Obstetrics and Gynaecology</i> , 2019, 39, 271-272.	0.4	4

#	ARTICLE	IF	CITATIONS
37	Vaccine-induced thrombosis and thrombocytopenia (VITT) in Ireland: A review of cases and current practices. <i>Thrombosis Update</i> , 2021, 5, 100086.	0.4	4
38	Enhanced VWF clearance in low VWF pathogenesis: limitations of the VWFpp/VWF:Ag ratio and clinical significance. <i>Blood Advances</i> , 2023, 7, 302-308.	2.5	3
39	Illustrated State-of-the-Art Capsules of the ISTH 2021 Congress. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12532.	1.0	2
40	Novel Insights into the Clinical Phenotype and Pathophysiology Underlying Low VWF Levels: The Low Von Willebrand Factor in Ireland Cohort (LoVIC) Study. <i>Blood</i> , 2016, 128, 873-873.	0.6	2
41	Recurrent lower limb venous thrombosis associated with a congenitally absent infrarenal inferior vena cava. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2016, 109, 57-57.	0.2	1
42	SIPPET: insights into factor VIII immunogenicity. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 36-38.	1.9	1
43	The impact of foetal restrictions on mode of delivery in women with inherited bleeding disorders. <i>European Journal of Haematology</i> , 2020, 105, 555-560.	1.1	1
44	Younger Age at Diagnosis Is Associated with an Increased Risk of Venous Thromboembolism in Multiple Myeloma. <i>Blood</i> , 2018, 132, 1223-1223.	0.6	1
45	Bleeding disorders in girls and women: setting the scene. <i>The Journal of Haemophilia Practice</i> , 2019, 6, 3-9.	0.2	1
46	Online Search Trends Influencing Anticoagulation in Patients With COVID-19: Observational Study. <i>JMIR Formative Research</i> , 2021, 5, e21817.	0.7	0
47	Preparing for menarche: treatment and management of heavy periods in women with bleeding disorders. <i>The Journal of Haemophilia Practice</i> , 2019, 6, 24-27.	0.2	0
48	Administration of Neuraxial Anesthesia in Adults with Pre-Existing Bleeding Disorders and Tendencies: Methodology for Delphi Consensus Recommendations. <i>Blood</i> , 2020, 136, 29-29.	0.6	0